Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
320.37M | 338.69M | 320.37M | 280.98M | 282.13M | 224.30M | Gross Profit |
4.77M | 39.27M | 4.64M | 51.99M | 99.70M | 73.19M | EBIT |
-33.83M | -7.36M | -36.47M | 12.53M | 67.40M | 44.31M | EBITDA |
-12.31M | 28.42M | -22.15M | 35.72M | 83.35M | 58.55M | Net Income Common Stockholders |
-51.44M | -19.56M | -51.44M | 7.77M | 47.26M | 31.34M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
4.38M | 68.28M | 95.71M | 37.53M | 136.30M | 17.21M | Total Assets |
76.29M | 756.58M | 689.09M | 575.78M | 595.04M | 375.98M | Total Debt |
8.84M | 94.12M | 113.66M | 21.22M | 18.00M | 37.43M | Net Debt |
4.46M | 25.84M | 17.96M | -16.31M | -118.30M | 20.23M | Total Liabilities |
38.93M | 399.33M | 307.86M | 154.10M | 173.87M | 198.31M | Stockholders Equity |
37.35M | 357.24M | 381.23M | 421.68M | 421.17M | 177.66M |
Cash Flow | Free Cash Flow | ||||
-16.41M | 2.43M | -20.25M | -69.64M | -16.61M | 8.86M | Operating Cash Flow |
36.48M | 89.40M | 36.48M | 5.46M | 57.35M | 49.48M | Investing Cash Flow |
-59.51M | -91.02M | -59.51M | -78.44M | -80.84M | -42.56M | Financing Cash Flow |
84.55M | -25.32M | 84.55M | -26.87M | 130.93M | -6.73M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | CHF4.05B | 33.64 | 8.87% | 1.57% | 4.84% | 7.45% | |
74 Outperform | CHF4.38B | 26.14 | 18.36% | 0.40% | 1.82% | 39.11% | |
73 Outperform | CHF1.01B | 7.76 | 29.55% | 3.26% | 182.25% | ― | |
61 Neutral | CHF706.87M | ― | ― | 3.15% | 62.88% | ||
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% |
PolyPeptide Group AG has expanded its revolving credit facility by EUR 40 million to EUR 151 million, with an extension until March 2028, supported by UBS, Danske Bank, and Zürcher Kantonalbank. This financial boost, alongside increased support from main shareholder Draupnir Holding B.V., enhances PolyPeptide’s financial flexibility to pursue growth, aiming to double its 2023 revenues by 2028, particularly in the metabolic diseases and GLP-1 sectors.
The most recent analyst rating on (CH:PPGN) stock is a Hold with a CHF33.50 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.
At the fourth ordinary General Meeting, PolyPeptide Group AG’s shareholders approved all Board of Directors’ proposals, including re-elections and the introduction of new authorized and conditional share capital. These decisions are expected to strengthen the company’s financial structure and governance, potentially enhancing its market position and stakeholder confidence.
PolyPeptide Group AG has announced the agenda for its fourth ordinary General Meeting in April 2025, where key board members will stand for re-election, and a new independent member, Jo LeCouilliard, is proposed for election. The meeting will also address the introduction of authorized and conditional share capital to enhance financial and strategic flexibility, alongside other standard agenda items such as re-election of auditors and approval of financial statements.
PolyPeptide Group AG reported significant improvements in profitability and cash flow for 2024, with a revenue increase of 5.1% compared to 2023. The company is poised for strong growth, driven by operational performance and capacity expansion projects in Belgium, France, and Sweden. For 2025, PolyPeptide forecasts accelerated revenue growth of 10% to 20%, supported by new commercial production in Belgium, and plans to continue increasing its EBITDA margin. The nomination of Joanna LeCouilliard to the Board of Directors is expected to bring valuable expertise in finance and healthcare management.